Ironwood Begins to Rebolster its Pipeline with Cour’s Rare Disease Drug

By Lucy Haggerty

Pharma Deals Review: Vol 2021 Issue 11 (Table of Contents)

Published: 12 Nov-2021

DOI: 10.3833/pdr.v2021.i11.2645     ISSN: 1756-7874

Section: Licensing



In an attempt to rebuild its pipeline, Ironwood Pharmaceuticals has agreed to collaborate with Cour Pharmaceuticals to develop and commercialise the latter’s investigational candidate, CNP-104, in the US...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details